Company: CSTL
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001447362-25-000097
Chunk: 195

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-08-04
Form: 10-Q
Item: Item 2
Chunk 195
---
$(3,467)

37

The following table provides a disaggregation of net revenues by type (in thousands):

Six Months EndedJune 30,20252024Change(unaudited)Dermatologic(1)$119,259 $128,163 $(8,904)Non-Dermatologic(2)54,917 31,813 23,104 Total net revenues$174,176 $159,976 $14,200 

(1)Consists of DecisionDx-Melanoma, DecisionDx-SCC and our Diagnostic GEP offering. 

(2)Consists of TissueCypher, DecisionDx-UM and IDgenetix.

The following table presents the calculation of gross margin (in thousands, except percentages):

 Six Months EndedJune 30, 20252024Change(unaudited)Net revenues$174,176 $159,976 $14,200 Less: Cost of sales (exclusive of amortization of acquired intangible assets)34,009 28,413 5,596 Less: Amortization of acquired intangible assets30,286 4,494 25,792 Gross margin$109,881 $127,069 $(17,188)Gross margin percentage63.1 %79.4 %(16.3)%

Net Revenues

Net revenues for the six months ended June 30, 2025 increased by $14.2 million, or 8.9%, to $174.2 million compared to the six months ended June 30, 2024, due to a $23.1 million increase in revenue from our non-dermatologic tests and a $8.9 million decrease in revenue from our dermatologic tests.

The $23.1 million increase in revenue from our non-dermatologic tests was largely attributable to a 102.2% increase in tests report volumes for our TissueCypher test, and, to a much lesser extent, a higher realized ASP. Increases in our TissueCypher test report volumes reflect growth through our sales force efforts. Net revenue from our non-dermatologic tests as a percentage of total net revenue increased from 19.9% for the six months ended June 30, 2024 to 31.5% for the six months ended June 30, 2025.

The $8.9 million decrease from our dermatologic tests was primarily due